Fairvalue-Calculator Fairvalue-Calculator
EN DE

Orient Pharma Co (4166) Fair Value & Analysis

Healthcare · TW · Market cap 6.3B TWD

Price24.80 TWD
Fair Value20.17 TWD
Upside-18.7%
Quality95/100
Evidence: High Range 14.64 TWD – 25.25 TWD

Fair value as of: Jun 24, 2026

Analysis

Orient Pharma Co (4166) currently trades at 24.80 TWD, while our model-based Fair Value estimate is 20.17 TWD — implying the stock looks roughly 18.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Orient Pharma Co (4166) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 20.17 TWD versus a price of 24.80 TWD — about −19% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4166?
Our 21-model fair value for Orient Pharma Co is 20.17 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 24.80 TWD.
What is the quality score of 4166?
Orient Pharma Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.